Sign in
AUTL Stock Price, Chart, Stats & News
Autolus Therapeutics plc
Save
423.17M
Market cap
–
Current P/E
–
Forward P/E
AUTL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -309.45% |
Operating margin | -859.61% |
Pretax margin | -430.66% |
Net margin | -439.68% |
Effective tax rate | -2.10% |
ROA | -38.16% |
ROE | -77.44% |
D/E | 0.40x |
Interest coverage ratio | 43.21x |
AUTL valuation
P/E | – |
P/S | 6.30x |
P/B | 1.81x |
P/CF | -1.14x |
P/FCF | -1.05x |
P/OCF | -1.14x |
PEG | -1.22x |
EV multiple | -1.41x |
About
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL.
Similar securities
Based on sector and market capitalization
Report issue